Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Parathormone (human recombinant)

Known as: parathyroid hormone (1-84) human recombinant, rhPTH, rhPTH(1-84) 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Recombinant parathyroid hormone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
BACKGROUND Impaired mineral homeostasis affecting calcium, phosphate, and magnesium is a result of parathyroid hormone (PTH… Expand
  • table I
  • figure 1
  • table II
  • figure 2
  • table III
Is this relevant?
2013
2013
Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China.
BACKGROUND Recombinant human parathyroid hormone (1-34) (rhPTH (1-34)) is the first agent in a unique class of anabolic therapies… Expand
Is this relevant?
Review
2012
Review
2012
The future of osteoporosis treatment - a research update.
  • K Lippuner
  • Swiss medical weekly
  • 2012
    • Corpus ID: 36985145
Osteoporosis is characterised by a progressive loss of bone mass and microarchitecture which leads to increased fracture risk… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 1
  • figure 2
Is this relevant?
2011
2011
Teriparatide [rhPTH (1-34)], but not strontium ranelate, demonstrated bone anabolic efficacy in mature, osteopenic, ovariectomized rats.
We compared teriparatide (TPTD) and strontium ranelate (SR) efficacy on bone formation activity in a mature rat model of estrogen… Expand
Is this relevant?
2010
2010
Osteoanabolic therapy: a non-surgical option of treatment for Kümmell’s disease?
Kümmell’s disease is the current eponym of avascular osteonecrosis (AVN) of a vertebral body leading to a delayed non-healing… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2009
2009
Teriparatide Following Bisphosphonates: Initial and Long-Term Effects on Microarchitecture and Bone Remodeling at the Human Iliac Crest
Since the approval of teriparatide for clinical application, a number of iliac crest studies have focused on increases in bone… Expand
Is this relevant?
2009
2009
Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis
SummaryThe level of increased bone formation after 24 months of treatment with teriparatide (rhPTH (1–34), TPTD) is similar in… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2007
2007
Patient willingness to take teriparatide.
OBJECTIVE Teriparatide [rhPTH (1-34)] is an effective treatment for osteoporosis administered by daily subcutaneous injection… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2006
2006
Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis
IntroductionTeriparatide [rhPTH (1–34)] reduces fracture risk, and in a published meta-analysis of clinical trials, teriparatide… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.
INTRODUCTION We evaluated effects of teriparatide (rDNA origin) injection [teriparatide, rhPTH (1-34), TPTD] on hip structure… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE